|
IQVIA™ Real-World Insights Bibliography
| The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
|
| Author(s): Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens
Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore,
Aida Aydemir, Irene Bezemer & Meritxell Sabidó
|
| Affiliations(s): "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia;
b The Alfred Hospital, Melbourne, VIC, Australia;
c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden;
d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland;
e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany;
f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland;
g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland;
h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway;
i Department of Clinical Medicine, University of Bergen, Bergen, Norway;
j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark;
k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France;
m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA;
n Global Epidemiology, IQVIA, Amsterdam, The Netherlands;
o Merck Healthcare KGaA, Darmstadt, Germany"
|
| Publication(s): |
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders,
2023 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Population Based Study, |
|
 |
| |
| |
| Burden of Hospitalizations and Outpatient Visits Associated With Moderate and Severe Acute Graft-Versus-Host Disease in Finland and Sweden: A Real-World Data Analysis |
| Author(s): Lorenzo Sabatelli, PhD,1 Mikko Keränen, MD, PhD,2 Elisabet Viayna, PhD,3 Montserrat Roset, BSc Stats,3 Nuria Lara, MD, MSc,3 Daniel Thunström, MSc Pharm,1 Minja Pfeiffer, PhD,1 Malin Nicklasson, MSc Pharm,4 Maija Itälä-Remes, MD, PhD5
|
| Affiliations(s): "1Incyte Biosciences International Sàrl, Morges, Switzerland; 2Helsinki University Hospital, Helsinki, Finland; 3IQVIA Real World Solutions, Barcelona, Spain; 4Department of Hematology and Coagulation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 5Turku University Hospital, Turku, Finland "
|
Publication(s): Supportive Care in Cancer
|
| Document Type(s): Article, |
| Countries: Finland, Spain, Sweden, Switzerland, |
C:
Y: |
Health economics, Transplant,
2022 |
|
L:
A: |
English
Clinical setting: hospital, Observational study, Population Based Study, |
|
|
| |
| |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets |
| Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group |
| Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
2The Alfred Hospital, Melbourne, Australia.
3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France.
4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).
5Global Database Studies, IQVIA, Tartu, Estonia.
6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands.
7IQVIA (former EPID Research), Espoo, Finland.
8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. |
Publication(s): Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
|
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Drug safety, Neurological disorders,
2022 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension |
| Author(s): Allan Lawrie1,2|Neil Hamilton3|Steven Wood2,4|Fernando Exposto5|Ruvimbo Muzwidzwa5|Louise Raiteri5|Amélie Beaudet6|Audrey Muller6|Rafael Sauter6|Nadia Pillai6|David G. Kiel |
| Affiliations(s): 1National Heart and Lung Institute,Imperial College London, London, UK2Insigneo Institute for Inâ€Silico Medicine,University of Sheffield, Sheffield, UK3Sheffield Pulmonary Vascular DiseaseUnit, Sheffield Teaching Hospitals NHSFoundation Trust, Royal HallamshireHospital, Sheffield, UK4Scientific Computing, Sheffield TeachingHospitals NHS Foundation Trust, RoyalHallamshire Hospital, Sheffield, UK5IQVIA, London, UK6Actelion Pharmaceuticals Ltd.,Allschwil, Switzerland7Department of Infection, Immunity andCardiovascular Disease, University ofSheffield, Sheffield, UK |
Publication(s): Pulmonary Circulation. 2022;12:e12136.wileyonlinelibrary.com/journal/pul2|1of10https://doi.org/10.1002/pul2.12136
|
| Document Type(s): Article, |
| Countries: Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Respiratory disease,
2022 |
|
L:
A: |
English
Observational study, Retrospective cohort analysis, |
|
|
| |
| |
| A novel decision model to predict the impact of weight management interventions: The Core Obesity Model. |
| Author(s): Sandra Lopes 1, Henrik H Meincke 1, Mark Lamotte 2, Anamaria-Vera Olivieri 3, Michael E J Lean 4
|
| Affiliations(s): 1Novo Nordisk A/S Søborg Denmark.
2IQVIA Zaventem Belgium.
3IQVIA Basel Switzerland.
4Human Nutrition School of Medicine, Dentistry and Nursing Royal Infirmary University of Glasgow Glasgow UK. |
Publication(s): Obesity Science & Practice 2021. https://doi.org/10.1002/osp4.495
|
| Document Type(s): Article, |
| Countries: Belgium, Switzerland, |
| Click here for the abstract |
C:
Y: |
Health economics, Obesity,
2021 |
|
L:
A: |
English
Clinical setting: Primary care, Cost effectiveness, |
|
|
| |
| |
| Identification of potentially undiagnosed patients with nontuberculous mycobacterial lung disease using machine learning applied to primary care data in the UK |
| Author(s): Orla M Doyle 1 2, Roald van der Laan 3 2, Marko Obradovic 4 2, Peter McMahon 5, Flora Daniels 6, Ashley Pitcher 7, Michael R Loebinger 8 |
| Affiliations(s): Predictive Analytics, Real World Analytical Solutions, IQVIA, London, UK.
2These authors contributed equally.
3Insmed Utrecht, Utrecht, The Netherlands.
4Insmed Utrecht, Utrecht, The Netherlands marko.obradovic@insmed.com.
5Real-World Insights, IQVIA, London, UK.
6Real-World Insights, IQVIA, Basel, Switzerland.
7Real-World Insights, IQVIA, Copenhagen, Denmark.
8Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, London, UK. |
Publication(s): PMID: 32430411 DOI: 10.1183/13993003.00045-2020
|
| Document Type(s): Article, |
| Countries: Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Database Validity and methodology, Pain,
2021 |
|
L:
A: |
English
Population Based Study, Real World Evidence, Retrospective database analysis, |
|
|
| |
| |
| Burden of pulmonary arterial hypertension in England: retrospective HES database analysis
|
| Author(s): Fernando Exposto 1, Ruben Hermans 2, Åsa Nordgren 2, Luke Taylor 2, Sanam Sikander Rehman 2, Robert Ogley 2, Evan Davies 3, Amina Yesufu-Udechuku 4, Amélie Beaudet |
| Affiliations(s): IQVIA, 210 Pentonville Road, London, N1 9JY, UK.
2IQVIA, London, UK.
3Actelion Pharmaceuticals Ltd, Allschwil, Basel-Landschaft, Switzerland.
4Actelion Pharmaceuticals UK Ltd, High Wycombe, UK. |
Publication(s): Ther Adv Respir Dis. 2021 Jan-Dec; 15: 1753466621995040.
Published online 2021 Feb 23. doi: 10.1177/1753466621995040
|
| Document Type(s): Article, |
| Countries: Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Respiratory disease,
2021 |
|
L:
A: |
English
Burden of illness, |
|
|
| |
| |
| Bridging the Gap Between RCTs and RWE Through Endpoint Selection
|
| Author(s): Robert J LoCasale 1, Chris L Pashos 2, Ben Gutierrez 3, Nancy A Dreyer 4, Toby Collins 5, Alan Calleja 5, Michael J Seewald 6, Jonathan M Plumb 7, Johan Liwing 8, Maurille Feudjo Tepie 9, Sajan Khosla 10 |
| Affiliations(s): 1Real World Evidence, Sanofi, Bridgewater, NJ, USA.
2AbbVie, Chicago, IL, USA.
3GSK, Philadelphia, PA, USA.
4IQVIA, Real-World Solutions, Cambridge, MA, USA.
5IQVIA, Real-World Solutions, London, UK.
6Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland.
7Ferring Pharmaceuticals SA, St Prex, Switzerland.
8CellProtect Nordic Pharmaceuticals, Stockholm, Sweden.
9Center for Observational Research, Amgen, Cambridge, UK.
10Real-World Evidence Center of Excellence, AstraZeneca, Cambridge, UK. sajan.khosla@astrazeneca.com. |
Publication(s): Published online 2020 Jul 6. doi: 10.1007/s43441-020-00193-5
|
| Document Type(s): Article, |
| Countries: Sweden, Switzerland, UK, USA, |
| Click here for the abstract |
C:
Y: |
Health status & patient reported outcomes,
2020 |
|
L:
A: |
English
Real World Data, Real World Evidence, |
|
|
| |
| |
| External Validation of the Core Obesity Model to Assess the Cost Effectiveness of Weight Management Interventions |
| Author(s): Sandra Lopes 1, Pierre Johansen 2, Mark Lamotte 3, Phil McEwan 4, Anamaria-Vera Olivieri 5, Volker Foos 4 |
| Affiliations(s): 1Novo Nordisk A/S, Søborg, Denmark. snlb@novonordisk.com.
2Novo Nordisk A/S, Søborg, Denmark.
3IQVIA, Zaventem, Belgium.
4Health Economics and Outcomes Research Ltd, Cardiff, UK.
5IQVIA, Basel, Switzerland. |
Publication(s): Pharmacoeconomics 2020 https://doi.org/10.1007/s40273-020-00941-3 + Pharmacoeconomics. 2021 Jan;39(1):137-138. doi: 10.1007/s40273-020-00982-8. Epub 2020 Nov 30
|
| Document Type(s): Article, |
| Countries: Belgium, Denmark, Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Health economics, Obesity,
2020 |
|
L:
A: |
English
Clinical setting: Primary care, Cost effectiveness, |
|
|
| |
| |
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab)
Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries |
| Author(s): Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi |
| Affiliations(s): IQVIA, Courbevoie, France;
Janssen EMEA, Medical Affairs, Italy;
Janssen EMEA, Medical Affairs, UK |
Publication(s): Presented at ISPE’s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk
Management (ICPE 2019), August 24–28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA.
|
| Document Type(s): Poster, |
| Countries: Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland, |
| Click here for the abstract |
C:
Y: |
Hematology, Oncology,
2019 |
|
L:
A: |
English
Public Health, Survey research, |
|
|
| |
| |
 1 of 3 
|
|
